![Alison Milhous](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Fortuna: 6 418 $ al 31/05/2026
Alison Tjosvold Milhous currently works at VivoSim Labs, Inc., as Independent Director from 2020 and Erasca, Inc., as Vice President-Accounting from 2021.
Ms. Milhous also formerly worked at Grant Thornton LLP, as Audit Partner from 2015 to 2019.
Ms. Milhous received her undergraduate degree from California Polytechnic State University (San Luis Obispo).
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
VIVOSIM LABS INC 0,19 % | 17/10/2025 | 4.899 ( 0,19 % ) | 6 418 $ | 31/05/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| VIVOSIM LABS, INC. | Director/Miembro de la Junta | 15/09/2020 |
| ERASCA, INC. | Comptroller/Controller/Auditor | 01/11/2021 |
| Empresas | Cargo | Fin |
|---|---|---|
Grant Thornton LLP
 Grant Thornton LLP Miscellaneous Commercial ServicesCommercial Services Provides accounting, assurance, tax and advisory services | Corporate Officer/Principal | 01/09/2019 |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 4 |
|---|---|
VivoSim Labs, Inc.
 VivoSim Labs, Inc. BiotechnologyHealth Technology Engages in developing and commercializing functional human tissues | Health Technology |
Grant Thornton LLP
Grant Thornton LLP Miscellaneous Commercial ServicesCommercial Services Provides accounting, assurance, tax and advisory services | Commercial Services |
California Polytechnic State University (San Luis Obispo)
 California Polytechnic State University (San Luis Obispo) Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Erasca, Inc.
 Erasca, Inc. Pharmaceuticals: MajorHealth Technology Develops, discovers and commercializes therapies for RAS/MAPK pathway-driven cancers | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.
